Worldwide Clinical Trials

JULY 8, 2024

Radiolabeled Antibodies : Various antibodies are being radiolabeled to target specific cancer antigens, enhancing both diagnostic accuracy and therapeutic efficacy. Hormonal Status : A body’s hormones, such as levels of reproductive hormones and thyroid function, can impact tissue responses to radiation therapy.

Hormones 130

Hormones Regulation Clinical Trials Clinical Trials 130

Pharmaceutical Technology

FEBRUARY 23, 2023

Adlai Nortye utilizes PAINT-2D and ANEAT-Id platform technologies to identify and develop immunotherapies and antibodies. It is also evaluating AN1004 to treat human epidermal growth factor receptor-2-negative metastatic breast cancer; AN4005 against advanced tumors; AN3025 and AN6025 for solid tumors.

Hormones 130

Hormones Development Drugs Clinical Trials 130

pharmaphorum

NOVEMBER 6, 2020

Its lead candidate in clinical development is VLS-101, an antibody-drug conjugate (ADC) targeting ROR1 that is being tested in a phase 1 and a phase 2 clinical trial for patients with blood cancer and solid tumours, respectively. Patients in that trial had been heavily pretreated and had failed to respond to other anticancer drugs.

Antibody 85

Antibody Hormones Trials Clinical Trials 85

Pharmaceutical Technology

SEPTEMBER 13, 2022

Hormone receptor-positive/human epidermal growth factor negative (HR+/HER2-) breast cancer accounts for approximately 70% of all breast cancers, with close to 40,000 new cases diagnosed each year worldwide. Trop-2 is highly expressed across multiple cancer types, with expression detected in more than 90% of breast cancers.

HR 162

HR Marketing Hormones FDA Approval 162

pharmaphorum

JULY 14, 2022

The antibody-drug conjugate (ADC) was turned down by NICE in draft guidance published earlier this year, leading to concerns of a disparity in access to the drug as the Scottish Medicines Consortium (SMC) had already cleared its use.

Drugs 104

Drugs Hormones Genomics Genome 104

pharmaphorum

FEBRUARY 21, 2022

” The antibody-drug conjugate is already approved as a third-line therapy for HER2-positive metastatic breast cancer and a second-line therapy for HER2-positive metastatic gastric cancer, and recent data from the DESTINY-Breast03 study looks set to expand its use into second-line treatment in breast cancer. AZ paid a hefty $1.4

Trials 132

Trials Sales Hormones Drugs 132

pharmaphorum

APRIL 25, 2022

The Swiss pharma said in its update that the acelERA trial comparing giredestrant to physician’s choice of endocrine therapy for previously-treated hormone receptor (HR)-positive, HER2-negative breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). Diagnostic led the charge, rising 24% to CHF 5.3

Trials 69

Trials Hormones HR Sales 69

XTalks

DECEMBER 5, 2024

Unlike the reigning blockbuster GLP-1 drugs on the market namely Novo Nordisks Wegovy (semaglutide) and Eli Lillys Zepbound (tirzepatide), the latter of which is a dual agonist of the GLP-1 and GIP receptors Amgens MariTide is an antibody-peptide conjugate that combines a GLP-1 receptor agonist (consisting of two peptides that mimic the GLP-1 hormone) (..)

Trials 104

Trials Drugs Clinical Trials Clinical Trials 104

XTalks

NOVEMBER 5, 2024

SEP-786, an oral parathyroid hormone 1 receptor (PTH1R) agonist, aims to restore essential mineral balance. Septerna’s thyroid-stimulating hormone receptor (TSHR) modulators offer a potentially disease-modifying oral treatment. Phase I trials are underway, with data expected in mid-2025. million patients in the US.

Drugs 59

Drugs Hormones Protein Antibody 59

XTalks

DECEMBER 5, 2024

Unlike the reigning blockbuster GLP-1 drugs on the market — namely Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide), the latter of which is a dual agonist of the GLP-1 and GIP receptors — Amgen’s MariTide is an antibody-peptide conjugate that combines a GLP-1 receptor agonist (consisting of two peptides that mimic the GLP-1 (..)

Trials 96

Trials Drugs Clinical Trials Clinical Trials 96

Pharmaceutical Technology

FEBRUARY 18, 2023

It was also under development for the treatment of diabetic nephropathy associated with chronic kidney disease, pediatric nephrotic syndrome, metastatic hormone-refractory prostate cancer, hypertension, diabetic neuropathic pain and ovarian cancer Chinook Therapeutics Overview Chinook Therapeutics, Inc (Chinook).,

Hormones 100

Hormones Development Production Clinical Trials 100

XTalks

MARCH 29, 2021

Related: Maternal Antibodies: How Allergies Can be Passed from Mothers to Children. They also believe caffeine could potentially disrupt fetal stress hormones, putting infants at risk for rapid weight gain after birth and for chronic conditions such as obesity, heart disease and diabetes later on in life.

Genotype 98

Genotype Allergies Hormones Research 98

The Pharma Data

JUNE 26, 2021

Chemist Han Xiao at Rice and biologist Xiang Zhang at Baylor and their labs have developed an antibody conjugate called BonTarg that delivers drugs to bone tumors and inhibits metastasis. Harnessing the power of antibodies to fight bone metastasis. “We feel our strategy is a real game changer.” Science Advances, 2021.

Drugs 52

Drugs Antibody Clinical Trials Clinical Trials 52

pharmaphorum

SEPTEMBER 14, 2020

US-based Merck, known as MSD outside North America, will globally develop and market Seattle’s investigational antibody-drug conjugate (ladiratuzumab vedotin). Merck & Co has signed a multi-billion cancer drug development deal, which will see it investing $1 billion in partner Seattle Genetics. billion equity investment in 5.0

Genetics 52

Genetics Development Drugs Protein 52

XTalks

JULY 2, 2021

Currently, there is no scientific evidence to suggest that the vaccines induce any hormonal changes that would lead to irregular periods. However, the similarity between the two proteins is not great enough for anti-spike antibodies to cross-react with placental syncytin-1.

Vaccine 105

Vaccine Vaccination Protein Immune Response 105

pharmaphorum

JULY 13, 2022

Meanwhile, Merck is also working with Seagen on the development of antibody-drug conjugate ladiratuzumab vedotin – both alone and in combination with Keytruda – for prostate cancer as well as other solid tumours. It is rumoured to be near to announcing a $40 billion takeover bid for the biotech.

Licensing 52

Licensing Licensing Hormones Production 52

Roots Analysis

OCTOBER 24, 2023

This has led to their widespread production and extensive use in the treatment of various indications including hormonal imbalances, oncological disorders and respiratory disorders. Antibody-Drug Conjugates: ADCs are monoclonal antibodies (mAbs) attached to surface antigens by chemical or a liable linker.

Manufacturing 40

Manufacturing Hormones Contamination Containment 40

pharmaphorum

AUGUST 16, 2022

The deal gives it worldwide ownership of Trodelvy (sacituzumab govitecan), a first-in-class TROP2 antibody-drug conjugate drug it acquired as part of its $21 billion takeover of Immunomedics in 2020.

Licensing 52

Licensing Licensing Hormones Drugs 52

XTalks

SEPTEMBER 17, 2020

Symptoms and Etiology: Caused by an overproduction of growth hormone, acromegaly primarily affects adults. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed.

Trials 98

Trials Gene Hormones Clinical Trials 98

pharmaphorum

OCTOBER 12, 2022

Gilead Sciences will hear back from the FDA in February next year about its marketing application for Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer, billed by the drugmaker as a key new indication for the drug.

HR 52

HR Sales Antibody Hormones 52

The Pharma Data

JANUARY 7, 2021

He also noted innovations are occurring with protein degraders, antibody conjugates, nanobodies and multi-specific antibodies, specifically bi- and tri-specific. To meet that goal, Sanofi is investing in areas like synthetic biology and cell and gene therapy. billion acquisition of Synthorx. Dupixent is currently approved in the U.S.

Protein 52

Protein Antibody Genetics Gene Therapy 52

pharmaphorum

JANUARY 10, 2023

The report also says late-stage rivals from Eli Lilly (donanemab) and possibly Roche (gantenerumab) may follow suit pending the results of ongoing trials; 7) Lenacapavir : Gilead Sciences’ first-in-class capsid inhibitor makes the grade for its potential to transform the treatment of HIV thanks to a twice-yearly dosing regimen.

Drugs 52

Drugs Gene Therapy Antibody Insulin 52

pharmaphorum

SEPTEMBER 9, 2022

Prospects for Gilead Sciences’ Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer continue to improve as data from the TROPiCs-02 trial strengthen, but the jury is still out on what that might mean for the drug commercially.

HR 52

HR Hormones Trials Sales 52

pharmaphorum

JULY 19, 2022

Merck said the LYNK-003 rial of Lynparza (olaparib) given as either a monotherapy or in combination with Roche’s CD20-targeting antibody Avastin (bevacizumab) in advanced colorectal cancer has been halted, as a look at the unblinded data showed little chance of a positive result.

Trials 52

Trials Hormones FDA Approval Drugs 52

Find Me Cure

OCTOBER 13, 2019

CDK4/6 inhibitors are used alongside hormone therapy. There are antibody drugs targetting those cells that are already FDA approved and there are antibody drugs still in trials. There are antibody drugs targetting those cells that are already FDA approved and there are antibody drugs still in trials.

Development 52

Development DNA Clinical Trials Clinical Trials 52

XTalks

MAY 10, 2023

The exact cause of lupus is not entirely understood, but it is thought to be from a combination of genetic, environmental and hormonal factors. GSK’s Benlysta (belimumab) is a monoclonal antibody that was approved by the US Food and Drug Administration (FDA) in 2011 for the treatment of SLE.

Drugs 52

Drugs Clinical Trials Clinical Trials Antibody 52

The Pharma Data

DECEMBER 27, 2020

“Combining ASC42 with ASC40, a fatty acid synthase (FASN) inhibitor or ASC41, a thyroid hormone receptor beta (THR-?) Viral hepatitis: (i) Hepatitis B: focus on breakthrough therapies for HBV clinical cure with subcutaneously injected PD-L1 antibody – ASC22 and Pegasys® as cornerstone drugs. (ii) ” About Ascletis.

Trials 40

Trials Hormones Development Drugs 40

XTalks

MARCH 8, 2024

Denosumab is a RANKL (receptor activator of nuclear factor kappa beta ligand) monoclonal antibody that blocks the ability of RANKL to bind to its receptor RANK. Risk factors include aging, hormonal changes, low body weight, low calcium intake and use of certain medications.

Drugs 59

Drugs FDA Approval Production Immune Response 59

Roots Analysis

MAY 21, 2024

In general, small molecule inhibitors, antisense oligonucleotides and monoclonal antibodies were utilized for protein degradation that binds to the specific pathogenic proteins to hinder their activity to obtain therapeutic results.

Protein 40

Protein Marketing Development Antibody 40

pharmaphorum

APRIL 28, 2022

But the company was inspired to re-brand its rare disease business unit as a response to internal ramp-ups that have occurred over the last few years, Helfgott said.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

The Pharma Data

AUGUST 6, 2020

As our understanding of breast cancer biology rapidly improves, we are working to identify new biomarkers and approaches to treatment for all forms of early and advanced breast cancer, including triple-negative and hormone receptor-positive. receptors.

Medicine 52

Medicine In-Vitro Protein Antibody 52

The Pharma Data

SEPTEMBER 19, 2020

As our understanding of breast cancer biology rapidly improves, we are working to identify new biomarkers and approaches to treatment for all forms of early and advanced breast cancer, including triple-negative and hormone receptor-positive. receptors.

HR 52

HR Medicine In-Vitro Development 52

Pharmaceutical Technology

FEBRUARY 5, 2023

The US Food and Drug Administration (FDA) has granted approval for Gilead Sciences ’ Trodelvy (sacituzumab govitecan-hziy) to treat unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer adult patients.

HR 264

HR Hormones FDA Approval Antibody 264

Pharmaceutical Technology

AUGUST 8, 2022

According to the trial data, Enhertu lowered disease progression or mortality risk by 50% compared with chemotherapy according to the physician’s choice in HER2-low metastatic breast cancer patients with hormone receptor (HR)-positive disease or HR-negative disease. months compared with 5.1 months for the chemotherapy arm.

FDA Approval 264

FDA Approval HR Clinical Trials Clinical Trials 264

pharmaphorum

MARCH 29, 2021

The EU looks set to approve emergency use of a third antibody therapy for COVID-19 after its human medicines committee backed use of Celltrion’s regdanvimab at its March meeting. . The EU’s medicines regulator is also reviewing COVID-19 antibodies from AstraZeneca , GlaxoSmithKline/Vir Biotechnology, and Brii Biosciences.

Antibody 78

Antibody Hormones Medicine Licensing 78

Pharmaceutical Technology

SEPTEMBER 28, 2022

Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted four new approvals for Merck ’s (MSD outside North America) humanised monoclonal antibody, Keytruda (pembrolizumab), to treat various types of cancers. With the latest development, the antibody is indicated for 23 usages in 13 different cancer types of cancer in the country.

Antibody 147

Antibody Clinical Trials Clinical Trials Hormones 147

Camargo

NOVEMBER 29, 2021

Monoclonal antibodies (mAbs). They may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system. Blood and blood components. Allergenics.

Development 180

Development Protein Production Hormones 180